Switzerland-based group Roche yesterday issued a press release announcing that its immunotherapy tecentriq (atezolizumab) has delivered positive results in combination with chemotherapy (carboplatin and Abraxane). The data have been collected during the Phase III IMpower131 clinical trial, conducted on patients with non-small cell lung cancer (NSCLC). Roche is largely investing on Tecentriq (monoclonal antibody), indeed it has many ongoing clinical trials aimed at providing evidences to improve the product’s market position. The drug competes with blockbusters Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb), which together generated 10x Tecentriq’s sales volume in 2017. Tecentriq, indeed, fetched the Basel-based group CHF487m in 2017, yet it may soon generate as much as $1.1bn.